Where the category stands in May 2026 — what's available, who to trust, what costs what. 22-min read, medically reviewed.
Read the guideAn independent overview of the compounded-GLP-1 telehealth market and the providers we cover — market size, what the FDA changed, and an honest read on each.
View the provider overviewOverview & reviewsPrimers for newcomers and deep dives for the curious. The foundation articles are published; more are in the pipeline.
View all Learn articlesWhat compounded and branded semaglutide and tirzepatide actually cost, from each provider's own published pricing.
Source-cited intelligence on compounded peptides and the regulatory landscape, written for prescribers and buyers. All three reports are still in production.
Reports are produced independently. We don't accept payment from manufacturers, pharmacies, or clinics for inclusion, and nothing here is sponsored. Each report will carry its reviewer and its sources when it publishes; none of them is finished, so none is available to download yet.
Three field reports are in production, and each will be free to read when it's done. There's no signup to join in the meantime — everything that will go into them is published as it happens in News and Regulatory updates.
Where 503A/503B supply stands after the 2025 delistings, compounded-GLP-1 pricing by channel, and what credentialed clinics are prescribing.
In preparationFDA compounding rules, the 503A bulks list, salt-form issues, and the PCAC timeline — in one map.
In preparationHow to validate a 503A/503B compounder — accreditation, inspection record, and the red flags.
In preparation